Ilex And Bioenvision Announce Completion Of Development Of An Oral Clofarabine Formulation

ILEX Oncology, Inc. and Bioenvision, Inc. announced that development of an oral formulation of clofarabine has been completed. The safety and tolerability of oral clofarabine will be evaluated in adult patients with locally advanced or metastatic solid tumors. ILEX Oncology Inc. has submitted the first part of a New Drug Application (NDA) with the U.S. Read more about Ilex And Bioenvision Announce Completion Of Development Of An Oral Clofarabine Formulation[…]

Bioenvision Completes Acquisition Of Pathagon

Bioenvision has closed its acquisition of Pathagon, a privately held company focused on the development of novel anti-infective products and technologies. With the acquisition, Bioenvision adds to its portfolio the rights to two FDA approved and marketed anti-infective technologies, OLIGON (TM) and methylene blue. Dr. Chris Wood MD, Bioenvision’s President & CEO, commented, “we are Read more about Bioenvision Completes Acquisition Of Pathagon[…]